Harvest Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.7M | Sell |
19,486
-34,712
| -64% | -$16.2M | 0.37% | 55 |
|
|
2025
Q4 | $24.4M | Buy |
54,198
+3,527
| +7% | +$1.52M | 0.92% | 20 |
|
|
2025
Q3 | $21.8M | Buy |
50,671
+1,156
| +2% | +$483K | 0.92% | 19 |
|
|
2025
Q2 | $22.1M | Buy |
49,515
+14,580
| +42% | +$6.72M | 1.04% | 16 |
|
|
2025
Q1 | $15.6M | Buy |
34,935
+19,710
| +129% | +$9.18M | 0.77% | 21 |
|
|
2024
Q4 | $6.08M | Buy |
15,225
+3,307
| +28% | +$1.53M | 0.28% | 58 |
|
|
2024
Q3 | $5.54M | Sell |
11,918
-101
| -0.8% | -$48.5K | 0.33% | 56 |
|
|
2024
Q2 | $5.63M | Buy |
12,019
+3,499
| +41% | +$1.52M | 0.41% | 45 |
|
|
2024
Q1 | $3.56M | Buy |
8,520
+5,194
| +156% | +$2.2M | 0.32% | 60 |
|
|
2023
Q4 | $1.33M | Sell |
3,326
-653
| -16% | -$241K | 0.21% | 66 |
|
|
2023
Q3 | $1.38M | Buy |
3,979
+766
| +24% | +$268K | 0.24% | 59 |
|
|
2023
Q2 | $1.13M | Buy |
3,213
+1,143
| +55% | +$385K | 0.23% | 59 |
|
|
2023
Q1 | $651K | Sell |
2,070
-1,114
| -35% | -$334K | 0.14% | 77 |
|
|
2022
Q4 | $903K | Buy |
3,184
+616
| +24% | +$188K | 0.23% | 61 |
|
|
2022
Q3 | $743K | Buy |
2,568
+2,118
| +471% | +$609K | 0.22% | 61 |
|
|
2022
Q2 | $127K | Hold |
450
| – | – | 0.04% | 254 |
|
|
2022
Q1 | $117K | Buy |
+450
| New | +$107K | 0.02% | 314 |
|
|
2021
Q3 | – | Sell |
-101
| Closed | -$20K | – | 818 |
|
|
2021
Q2 | $20K | Sell |
101
-151
| -60% | -$31.6K | ﹤0.01% | 622 |
|
|
2021
Q1 | $54K | Sell |
252
-635
| -72% | -$139K | 0.01% | 390 |
|
|
2020
Q4 | $209K | Sell |
887
-1,121
| -56% | -$257K | 0.02% | 150 |
|
|
2020
Q3 | $540K | Sell |
2,008
-50
| -2% | -$13.8K | 0.04% | 81 |
|
|
2020
Q2 | $589K | Buy |
2,058
+108
| +6% | +$29.3K | 0.05% | 61 |
|
|
2020
Q1 | $463K | Buy |
1,950
+423
| +28% | +$97K | 0.05% | 66 |
|
|
2019
Q4 | $358K | Buy |
1,527
+1,067
| +232% | +$216K | 0.04% | 77 |
|
|
2019
Q3 | $78K | Buy |
460
+124
| +37% | +$21.9K | 0.01% | 221 |
|
|
2019
Q2 | $62K | Sell |
336
-1,147
| -77% | -$201K | 0.01% | 265 |
|
|
2019
Q1 | $273K | Buy |
1,483
+599
| +68% | +$111K | 0.05% | 89 |
|
|
2018
Q4 | $146K | Hold |
884
| – | – | 0.03% | 144 |
|
|
2018
Q3 | $170K | Buy |
+884
| New | +$157K | 0.03% | 194 |
|
|
2018
Q2 | – | Sell |
-527
| Closed | -$85K | – | 337 |
|
|
2018
Q1 | $85K | Buy |
+527
| New | +$86.1K | 0.01% | 131 |
|
|
2017
Q4 | – | Sell |
-678
| Closed | -$103K | – | 252 |
|
|
2017
Q3 | $103K | Hold |
678
| – | – | 0.01% | 94 |
|
|
2017
Q2 | $87K | Buy |
+678
| New | +$81.6K | 0.01% | 107 |
|
Other funds holding VRTX
VCM
VPM
Harvest Fund Management's VRTX Position: Q1 2026 in Review
Harvest Fund Management reduced its Vertex Pharmaceuticals (VRTX) stake by 64% in Q1 2026, selling an estimated $16.2M and leaving 19,486 shares worth $8.7M. The position accounts for 0.37% of the portfolio, ranked #55.
Harvest Fund Management first reported a position in VRTX in Q2 2017 and has held it in 32 quarters since. The position peaked at $24.4M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Harvest Fund Management held 19,486 shares of Vertex Pharmaceuticals worth $8.7M as of Q1 2026.
- Harvest Fund Management sold 34,712 Vertex Pharmaceuticals shares in Q1 2026, an estimated $16.2M.
- Vertex Pharmaceuticals made up 0.37% of Harvest Fund Management's portfolio in Q1 2026, its #55 holding.
- Harvest Fund Management first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 32 quarters since.
- Harvest Fund Management's Vertex Pharmaceuticals position peaked at $24.4M in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Harvest Fund Management's 13F filing for Q1 2026, filed 14 May 2026.